SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

Pycnodysostosis (Pycno) is an autosomal recessive osteosclerotic skeletal dysplasia that is caused by the markedly deficient activity of cathepsin K. This lysosomal cysteine protease has substantial collagenase activity, is present at high levels in osteoclasts, and is secreted into the subosteoclastic space where bone matrix is degraded. In vitro studies revealed that mutant cathepsin K proteins causing Pycno did not degrade type I collagen, the protein that constitutes 95% of organic bone matrix. To determine the in vivo effects of cathepsin K mutations on bone metabolism in general and osteoclast-mediated bone resorption specifically, several bone metabolism markers were assayed in serum and urine from seven Pycno patients. Two markers of bone synthesis, type I collagen carboxy-terminal propeptide and osteocalcin, were normal in all Pycno patients. Tartrate-resistent acid phosphatase, an osteoclast marker, was also normal in these patients. Two markers that detect type I collagen telopeptide cross-links from the N and C termini, NTX and CTX, respectively, were low in Pycno. A third marker which detects a more proximal portion of the C terminus of type I collagen in serum, ICTP, was elevated in Pycno, a seemingly paradoxical result. The finding of decreased osteoclast-mediated type I collagen degradation as well as the use of alternative collagen cleavage sites by other proteases, and the accumulation of larger C-terminal fragments containing the ICTP epitope, established a unique biochemical phenotype for Pycno.


INTRODUCTION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

Pycnodysostosis (Pycno), an autosomal recessive sclerosing skeletal dysplasia, recently was shown by a positional cloning strategy to result from the deficient activity of the lysosomal cysteine protease, cathepsin K (EC 3.4.22.38).(1) The disease is characterized by reduced stature, osteosclerosis, acro-osteolysis of the distal phalanges, frequent fractures, clavicular dysplasia, and skull deformities with delayed suture closure.(2,3) The fact that Pycno resulted from deficient cathepsin K activity proved the important physiological role of this lysosomal cysteine protease in bone matrix degradation and implied that inhibition of cathepsin K activity might be therapeutic for bone diseases characterized by excessive bone degradation, such as osteoporosis and certain forms of arthritis.

The cathepsin K gene, which was cloned originally from rabbit osteoclasts(4) and subsequently from several human tissues,(5–8) was highly expressed in osteoclasts, the site of Pycno pathology.(9) Immunohistochemical and fluorescence microscopic studies detected cathepsin K protein in intracellular vacuoles which were fused with the ruffled border as well as in the subosteoclastic space,(10,11) the putative site of organic bone matrix degradation during bone resorption. Cathepsin K gene expression and protein were not detected in other bone cells such as osteoblasts in mature or developing bones.(10,12,13) Biochemical characterization of purified recombinant human cathepsin K revealed that the mature enzyme was a monomeric protein with an apparent molecular mass of about 29 kDa.(14) The enzyme had a broad bell-shaped pH activity profile, with an optimum at 6.1, and strong collagenolytic, elastase, and gelatinase activities, exceeding those of cathepsins S or L.

Among the cathepsin K mutations that have been identified in Pycno patients, all appeared to obliterate its enzymatic function.(1,15) Several of the genetic lesions were nonsense mutations, predicting termination of the protein prior to the critical cysteine or histidine residues in the active cleft which are required for proteolysis. A base substitution obliterated the stop codon and extended the protein by 19 residues at its C terminus, but was not immunologically detectable when expressed in vitro.(1) More recently, expression of five Pycno missense mutations in yeast revealed that four mutant cathepsin K proteins lacked all protease activity, while the fifth, Y212C, retained protease activity but had no detectable collagenase activity.(15) Thus, all cathepsin K mutations identified to date eliminated activity of the enzyme toward type I collagen.

While the impact of Pycno mutations on cathepsin K function has been studied in vitro, the specific effects of cathepsin K deficiency on organic bone matrix degradation in vivo have not been elucidated. To gain insights into those effects, markers of bone metabolism were assayed in serum and urine from Pycno patients. In this communication, we report significant decreases in the quantities of the cross-linked N- and C-telopeptides of type I collagen (NTX and CTX, respectively) in urine, and the paradoxical increase of the more proximal portion of the C terminus of type I collagen in the serum (ICTP) of Pycno patients. The identification of these unique bone metabolic abnormalities established the first biochemical phenotype for this lysosomal disorder, providing insights into the normal degradation of type I collagen by cathepsin K.

MATERIALS AND METHODS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

Patients and specimens

Blood and urine samples were obtained with informed consent from patients with Pycno, aged 6–21 years, all of who met the standard clinical criteria for this skeletal dysplasia.(16) For those patients whose cathepsin K defects had not be previously characterized, mutations were determined using exon and intron boundary amplification from genomic DNA and subsequent DNA sequencing on an ABI377 Sequencer (Perkin-Elmer Corp., Norwalk, CT, U.S.A.) as previously described.(15) Putative mutations were confirmed using restriction assays on PCR products amplified from genomic DNA; the possibility that these changes were polymorphisms was eliminated by documenting their absence in at least 100 normal alleles. Serum and urine samples were stored at –80°C until the various assays were performed.

Assays of bone metabolism markers

Bone metabolism markers that were determined included: osteocalcin (OC), the carboxy-terminal propeptide of type I procollagen (PICP), tartrate-resistant acid phosphatase (TRAP), ICTP, NTX, CTX, as well as urine pyridinoline (Pyr), and urine deoxypyridinoline (Dpyr). OC, PICP, TRAP, Pyr, and Dpyr were determined by the Nichols Institute (San Juan Capistrano, CA, U.S.A.) for the New York patients and by SRL Inc. laboratory (Tokyo, Japan) for the Japanese patients. OC was measured either by an immunoradiometric assay that detects both intact OC and the 1–43 OC fragment (Nichols Institute) or by a sandwich immunoassay that detected intact OC (SRL, Inc.).(17,18) PICP was measured in serum using a radioimmunoassay (Orion Diagnostica, Espoo, Finland). TRAP was measured within 1 week of blood drawing by enzymatic methods using either α-naphthyl phosphate (Nichols Institute) or p-nitrophenyl phosphate (SRL, Inc.) as substrate.(19,20) Pyr and Dpyr were assayed on morning urine void samples using high-performance liquid chromatography (HPLC). ICTP values were assayed from serum in the Renal Metabolism Laboratory at Children's Memorial Hospital (Chicago, IL, U.S.A.; courtesy of Dr. C.B. Langman) and at SRL using an radioimmunoassay produced by Orion Diagnostica. NTX values for the three New York patients as well as a large cohort of Israeli Arab Pycno patients were determined at the University of Washington (Seattle, WA, U.S.A.) as described previously,(21) while those for the Japanese patients were assayed by Mochida Pharmaceutical Co., Ltd. (Tokyo, Japan). Urine excretion of CTX was assayed at Fuji Revio, Inc. (Tokyo, Japan) (enzyme-linked immunosorbent assay [ELISA]; Osteometer A/S, Copenhagen, Denmark). NTX and CTX values were normalized to urine creatinine concentrations determined by the Jaffe procedure using a commercially available kit (Sigma Diagnostics, St. Louis, MO, U.S.A.) or the standard colorimetric procedure.

Statistics

The bone marker values were compared with age-appropriate normative values available in the laboratories performing the assays or, when unavailable, from the literature. Statistical comparisons for NTX values for the Pycno patients, and normal individuals were made using the unpaired two-tailed Student's t-test with significance level set at p ≤ 0.05.

RESULTS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

Among the seven Pycno patients who were studied with several markers of bone metabolism, sequencing of the seven coding exons of cathepsin K revealed two novel mutations (L9P and W298R) and three previously reported lesions (Fig. 1).(15) The genotypes of four Japanese patients included homoallelism for L9P in one patient, homoallelism for A277 V in two patients, and heteroallelism for L9P and W298R in one patient. The genotypes of three patients studied in New York were heteroallelism for R241X and Y212C in a Spanish patient and homozygosity for R312G in two siblings of Honduran descent.(15) For the larger cohort of Pycno patients for whom only NTX concentrations were measured, mutation analysis revealed 16 Israeli Arab patients who were homoallelic for X330 W,(1) a Canadian patient homoallelic for R241X, a previously reported Mexican-American boy with heteroallelism for G146R and R241X,(1) and two Swiss siblings homoallelic for A311P, a novel mutation affecting the mature enzyme.

thumbnail image

Figure FIG. 1. Cathepsin K mutations causing pycnodysostosis. Nine mutations were identified, including seven missense defects, one nonsense defect, and an alteration of the stop codon. The codon alteration and the predicted effects on the cathepsin prepropolypeptide are indicated, with each positioned in the relevant exon. Three of these mutations were novel (L9P, W298R, and A311P), while the remainder have been reported previously.(1,15) Most mutations affected the mature cathepsin K enzyme, but one (L9P) affected the preregion that is believed to be critical for transfer of the nascent protein to the endoplasmic reticulum.

Download figure to PowerPoint

To assess type I collagen synthesis rates and osteoblast activity, serum PICP and OC levels were determined. The values for both markers were within their respective normal ranges for six of seven Pycno patients, the sole exception being a 12-year-old girl of Honduran descent who had elevated levels (Table 1). These results were consistent with the view that the osteosclerosis observed in Pycno patients arises solely from inadequate bone resorption by osteoclasts.

Table Table 1. Markers of Bone Metabolism in Pycnodysostosis Patients
Thumbnail image of

To document the effects of the reduced bone resorption in Pycno, serum TRAP activity and ICTP were assayed, and the urine levels of Pyr, Dpyr, NTX, and CTX were determined. As shown in Table 1, the TRAP activities were normal in all seven Pycno patients, suggesting normal osteoclast numbers and differentiation. Urine Pyr and Dpyr levels were normal in four of the five patients studied; the fifth patient, a 6-year old Japanese Pycno patient had low levels of both. In contrast, NTX concentrations were below the normal range for five of six pediatric Pycno patients (with most being strikingly low), but a normal value was obtained for the sole adult Pycno patient. CTX concentrations were all extremely low in the four patients studied. Finally, ICTP values were greater than twice the upper level of normal in six Pycno patients. Thus, the NTX and CTX concentrations were low in Pycno, while ICTP was elevated. Urine Pyr and Dpyr were normal in the Pycno patients.

To document further the effects of cathepsin K deficiency on bone matrix degradation, the NTX assay was performed on a larger cohort which primarily included pediatric and adult Pycno patients from the large Israeli Arab family who participated in the positional cloning studies of this disorder.(1,22,23) As shown in Table 2, the mean NTX concentration in 17 affected children (aged 5–16 years) was significantly lower than the comparable mean value in 9 age-matched normal individuals. Similarly, the mean NTX concentration for six adult Pycno patients (aged 18–59 years) was significantly decreased compared with normal adults. Of note, there was some overlap in the NTX concentrations of the Pycno patients with the lower end of the age-appropriate normal ranges (data not shown), which may be attributable in part to the broad width of those ranges. Nonetheless, average NTX concentrations were decreased significantly in the pediatric and adult Pycno patients, documenting the role of cathepsin K in bone matrix degradation by osteoclasts during the relatively more active phase of linear growth as well as for baseline bone turnover in the mature skeleton.

Table Table 2. NTX Values in Pediatric and Adult Pycnodysostosis Patients
Thumbnail image of

DISCUSSION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

The measurement of several noninvasive markers of bone metabolism demonstrated apparently normal osteoblastic activity but deranged bone matrix degradation in patients with Pycno. The urine NTX concentrations, normalized to urine creatinine, were decreased in growing children and adults with Pycno, indicating reduced bone resorption. The mouse monoclonal antibodies used for the NTX ELISA recognize the N-telopeptide–to-helix pyridinoline cross-linking site of the α2 chain of human type I collagen, the major protein in organic bone matrix (Fig. 2).(21) Epitope recognition is conformation dependent (i.e., the peptide must be trivalent), and the antibody does not bind to comparable portions of type II collagen. In vitro studies have documented that cathepsin K cleaves type I collagen in the N-telopeptide as well as near the N terminus of the helical region of the α1 chain (Fig. 2).(24) This gives cathepsin K potent activity for releasing the NTX epitope from type I collagen, an activity that is significantly greater than that observed with cathepsin B, L, or S.(24,25) The demonstration of decreased NTX concentrations among Pycno patients, both adults and children, was consistent with a decreased rate of type I collagen degradation from bone secondary to the cathepsin K deficiency in osteoclasts, and confirmed the sensitivity of this assay for detecting decreases in bone resorption rates as has been documented with other metabolic bone disorders.(26,27)

thumbnail image

Figure FIG. 2. Cathepsin K proteolytic sites and bone marker epitopes at the N and C termini of type I collagen. Type I collagen, comprising two α1 and one α2 chains, is a triple helix except at the telopeptides which contain the cross-linking sites. Cathepsin K (Cat K) cleaves intact type I collagen at the three sites indicated in the telopeptides (L. Atley and D.R. Eyre, unpublished data) as well as at four specific sites in the helical domain (data not shown.(24) The epitopes in the N- and C-telopeptides detected by three bone markers (NTX, CTX, and ICTP) are indicated.

Download figure to PowerPoint

The normalized urine CTX concentration, which measured the C-telopeptide of type I collagen,(28) also was low in Pycno patients. This assay was performed with rabbit polyclonal antibodies that were raised against a synthetic peptide of the eight C-terminal residues of the type I collagen α1 chain, including the lysine residue that is part of the C-terminal cross-link (Fig. 2). It is believed that the CTX assay detects both cross-linked and non–cross-linked C-terminal telopeptides. As with the NTX assay, in vitro studies have shown that cathepsin K activity releases the CTX epitope from type I collagen.(24) The CTX results were consistent with those obtained for NTX, providing further evidence that type I collagen degradation in bone is diminished in Pycno. These findings also were consistent with the ultrastructural studies of bone from a Pycno patient which documented the presence of incompletely degraded collagen fibrils in vacuoles within osteoclasts.(9) While vacuolar transcytosis from the apical to the basolateral surface of osteoclasts has been shown to be the normal pathway for release of resorbed bone matrix proteins,(29,30) the observation of identifiable collagen fibrils within the Pycno osteoclasts is pathological.

Unlike patients with osteopetrosis (Albers–Schonberg disease) who appear to have absent or thoroughly ineffective osteoclasts, Pycno patients possess osteoclasts that have some degradative capacity. Cathepsin K–deficient osteoclasts appear to differentiate normally from their monocyte-macrophage precursors and possess an intact mechanism for demineralization.(9) The appendicular skeletal bones of young Pycno patients grow longer and wider, albeit more slowly than normal, and fracture healing generally proceeds normally. This bone-resorptive capacity occurs despite the fact that all Pycno cathepsin K mutations studied to date have no residual activity against type I collagen. Thus, cathepsin K–deficient osteoclasts are capable of degrading bone matrix, presumably with other proteases, either enzymes that normally contribute to bone resorption or others that are recruited for this purpose when cathepsin K is deficient. The aforementioned ultrastructural study of Pycno bone indicated that bone matrix resorption resulted from osteoclast-produced proteases, and not from other cell types, a finding substantiated by in vitro studies of Pycno osteoclast-like cells generated from circulating precursors (D. Brömme, D. Dempster, and B.D. Gelb, unpublished results).

In this context, the paradoxical finding that serum ICTP values were elevated in Pycno patients, while the NTX and CTX concentrations were reduced, provides insights into the function of cathepsin K in bone matrix degradation by osteoclasts. The ICTP assay uses polyclonal antiserum which was raised against cross-linked C-terminal fragments of type I collagen that had been digested with bacterial collagenase or trypsin.(31) The assay detects type I collagen cross-links that are trivalent and include a hydrophobic phenylalanine-rich domain of the two α1-chains located between the helix and the cross-link near the C terminus (Fig. 2).(32) The assay provides a sensitive indication of high or low bone turnover for some bone diseases,(33) but has not proven reliable in detecting the effects of treatments that affect bone density such as bisphosphonates for osteoporosis.(34,35) Since the collagen fragment detected by the ICTP assay has a molecular weight of around 10 kDa,(31) small enough to permit filtration at the glomerulus, significant renal dysfunction can also result in elevated serum ICTP values. Since Pycno patients have normal renal function and are not subject to excessive degradation of bone or soft tissue, the most likely explanation for the elevated serum ICTP values must be the generation of increased amounts of the C-terminal epitope detected by this assay despite an overall reduction in bone resorption. This implies that cathepsin K hydrolyzes collagen at its C terminus beyond the hydrophobic domain recognized by the ICTP assay. Alternatively, the C terminus may be liberated normally by another protease and then subsequently hydrolyzed further by cathepsin K. Isolation and amino acid sequencing of the type I collagen C-terminal fragments derived from cathepsin K–deficient osteoclasts could identify the cleavage sites, thereby providing insights into the substrate specificity of the residual or compensatory protease(s).

Urine Pyr and Dpyr concentrations were normal in nearly all of the Pycno patients, findings that were unexpected for a disorder with the decreased bone resorption by osteoclasts. Pyr and Dpyr, measured by the HPLC assay used for this study, are excreted in the urine in two forms, as free amino acids (hydroxylysylpyridinoline and lysylpyridinoline, respectively) and as small peptides containing those amino acids.(36) Pyr and Dpyr derive from the post-translational hydroxylation of lysine residues at sites near the N and C termini of collagen that become cross-linked. In urine, ∼67% of Pyr and Dpyr are in the form of small peptides while the remainder is free. In vitro studies have documented that osteoclasts release Pyr and Dpyr only as small peptides(37); degradation to the free forms is believed to occur in the liver and, possibly, the kidney.(38) Although collagens from several tissues have modified cross-linked lysine residues, urine Pyr and Dpyr are believed to derive principally from bone collagen. This is supported by the observation that the Pyr-to-Dpyr ratio in human bone is 3.5:1, similar to that found in urine and markedly different from collagens in other tissues which have considerably lower amounts of Dpyr (ratios > 9:1).(39) In Pycno patients, the Pyr-to-Dpyr ratio averaged 4.56, suggesting that urine Pyr and Dpyr were reflecting bone collagen resorption. Since both the NTX and CTX values were markedly reduced for these patients, these findings indicated that excretion of the free forms of Pyr and Dpyr constituted a larger percentage of the total. Consistent with the ICTP results, this suggests that cathepsin K–deficient osteoclasts degrade bone collagen into abnormally large fragments that are not filtered at the glomerulus but rather undergo extensive proteolysis in the liver and kidney. It is also inferred that the degree of impairment of bone matrix degradation in Pycno is not as severe as the NTX and CTX values implied, a view compatible with the observed skeletal phenotype.

In summary, the in vivo effects of cathepsin K deficiency on bone metabolism were examined in the osteosclerotic bone dysplasia, Pycno. Assays for bone formation, OC and PICP, indicated normal osteoblast activity in this disorder. Two urine markers of bone resorption, NTX and CTX, had decreased concentrations, consistent with diminished osteoclast-mediated bone matrix degradation due to cathepsin K deficiency. Another marker of bone resorption, serum ICTP, was increased, suggesting that the type I collagen degradation in bone resulted from the actions of other protease(s) using alternative cleavage sites near the C terminus. By characterizing these bone metabolism markers of type I collagen degradation in patients with Pycno, the decreased urine NTX and CTX and increased serum ICTP concentrations defined the biochemical phenotype of cathepsin K deficiency.

Acknowledgements

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

The authors thank the patients for their participation, Dr. C.B. Langman (Children's Memorial Hospital, Chicago, IL, U.S.A.) for performing ICTP assays, Mr. T. Matsuura (Biosciences Research Laboratory, Mochida, Japan) and Mr. N. Suzuki (Fuji Revio Inc., Hachiouji, Japan) for performing urine NTX and CTX assays, as well as Drs. Kumiko Araki (Kochi Medical School, Kochi, Japan) and Masaaki Yoshimoto (Children's Clinic Yoshimoto, Nagasaki, Japan) for enrolling patients. This work was supported in part by National Institutes of Health research grants (AR44231 to B.D.G., DK34045 to R.J.D., and AR37318 to D.E.E.), a grant from the National Center for Research Resources for the Mount Sinai General Clinical Research Center (RR00071), a grant for the Mount Sinai Child Health Research Center (HD28822), a grant from Ostex International, Inc. to D.E.E., and a grant from the Foundation for the Growth Science in Japan to Y.N.

REFERENCES

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES
  • 1
    Gelb BD, Shi GP, Chapman HA, Desnick RJ 1996 Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency Science 273:12361238.
  • 2
    Maroteaux P, Lamy M 1962 La pycnodysostose Presse Med 70:9991002.
  • 3
    Andren L, Dymling JF, Hogeman KE, Wendeberg B 1962 Osteopetrosis acro-osteolytica: A syndrome of osteopetrosis, acro-osteolysis and open sutures of the skull Acta Chir Scand 124:496507.
  • 4
    Tezuka K, Tezuka Y, Maejima A, Sato T, Nemoto K, Kamioka H, Hakeda Y, Kumegawa M 1994 Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts J Biol Chem 269:11061109.
  • 5
    Inaoka T, Bilbe G, Osamu I, Tezuka K-I, Kumegawa M, Kokubo T 1995 Molecular cloning of human cDNA for cathepsin K: Novel cysteine proteinase predominantly expressed in bone Biochem Biophys Res Commun 206:8996.
  • 6
    Shi G-P, Chapman HA, Bhairi SM, DeLeeuw C, Reddy VY, Weiss SJ 1995 Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2 FEBS Lett 357:129134.
  • 7
    Brömme D, Okamoto K 1995 Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary: Molecular cloning, sequencing and tissue distribution Biol Chem Hoppe-Seyler 376:379384.
  • 8
    Li Y-P, Alexander M, Wucherpfennig AL, Yelick P, Chen W, Stashenko P 1995 Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas J Bone Miner Res 10:11971202.
  • 9
    Everts V, Aronson DC, Beertsen W 1985 Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis Calcif Tissue Int 37:2531.
  • 10
    Littlewood-Evans A, Kokubo T, Ishibashi O, Inaoka T, Wlodarski B, Gallagher JA, Bilbe G 1997 Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry Bone 20:8186.
  • 11
    Kamiya T, Kobayashi Y, Kanaoka K, Nakashima T, Kato Y, Mizuno A, Sakai H 1998 Fluorescence microscopic demonstration of cathepsin K activity as the major lysosomal cysteine proteinase in osteoclasts J Biochem 123:752759.
  • 12
    Dodds RA, Connor JR, Drake F, Field J, Gowen M 1998 Cathepsin K mRNA detection is restricted to osteoclasts during fetal mouse development J Bone Miner Res 13:673682.
  • 13
    Yamaza T, Goto T, Kamiya T, Kobayashi Y, Sakai H, Tanaka T 1998 Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur Bone 23:499509.
  • 14
    Brömme D, Okamoto K, Wang BB, Biroc S 1996 Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts J Biol Chem 271:21262132.
  • 15
    Hou W-S, Brömme D, Zhao Y, Mehler E, Dushey C, Weinstein H, Sa Miranda C, Fragge C, Greig F, Carey J, Rimoin D, Desnick RJ, Gelb BD 1999 Cathepsin K: Characterization of novel mutations in the pro and mature polypeptide regions causing pycnodysostosis J Clin Invest 103:731738.
  • 16
    Sedano HP, Gorlin RJ, Anderson VE 1968 Pycnodysostosis: Clinical and genetic considerations Am J Dis Child 116:7077.
  • 17
    Diego EMD, Guerrero R, de la Piedra C 1994 Six osteocalcin assays compared Clin Chem 40:20712077.
  • 18
    Hosoda K, Eguchi H, Nakamoto T, Kubota T, Honda H, Jindai S, Hasegawa R, Kiyoki M, Yamaji T, Shiraki M 1992 Sandwich immunoassay for intact human osteocalcin Clin Chem 38:22332238.
  • 19
    Babson AL, Read PA, Phillips GE 1959 The importance of the substrate in assays of acid phosphatase in serum Am J Clin Pathol 32:8387.
  • 20
    Lau KHW, Onishi T, Wergedal JE, Singer FR, Baylink DJ 1987 Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption Clin Chem 33:458462.
  • 21
    Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine J Bone Miner Res 7:12511258.
  • 22
    Edelson JG, Obad S, Geiger R, On A, Artul HJ 1992 Pycnodysostosis: Orthopedic aspects with a description of 14 new cases Clin Orthop 280:263276.
  • 23
    Gelb BD, Edelson JG, Desnick RJ 1995 Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping Nat Genet 10:235237.
  • 24
    Garner P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaisse J-M 1998 The collagenolytic activity of cathepsin K is unique among mammalian proteinases J Biol Chem 273:3234732352.
  • 25
    Kafienah W, Brömme D, Buttle DJ, Croucher LJ, Hollander AP 1998 Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix Biochem J 331:727732.
  • 26
    Brenner RE, Vetter U, Bollen A-M, Morike M, Eyre DR 1994 Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta J Bone Miner Res 9:993997.
  • 27
    Hernandez MV, Peris P, Guanabens N, Alvarez L, Monegal A, Pons F, Ponce A, Munoz-Gome J 1997 Biochemical markers of bone turnover in Camurati-Engelmann disease: A report on four cases in one family Calcif Tissue Int 61:4851.
  • 28
    Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated Clin Chem 40:20222025.
  • 29
    Nesbitt SA, Horton MA 1997 Trafficking of matrix collagens through bone-resorbing osteoclasts Science 276:266269.
  • 30
    Salo J, Lehenkari P, Mulari M, Metsikkö K, Väänänen HK 1997 Removal of osteoclast bone resorption products by transcytosis Science 276:270273.
  • 31
    Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L 1993 Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation Clin Chem 39:635640.
  • 32
    Risteli J, Sassi M-L, Eriksen H, Niemi S, Mansell JP, Risteli L 1997 Epitope of the assay for the carboxyterminal telopeptide of human type I collagen (ICTP) J Bone Miner Res 12:S498.
  • 33
    Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J 1993 Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry J Bone Miner Res 8:127132.
  • 34
    Garner P, Shi WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment J Clin Endocrinol Metab 79:16931700.
  • 35
    Sairanen S, Tahtela R, Laitinen K, Loyttyniemi E, Valimaki MJ 1997 Effects of short-term treatment with clodronate on parameters of bone metabolism and their diurnal variation Calcif Tissue Int 60:160163.
  • 36
    Eyre DR 1997 Bone biomarkers as tools in osteoporosis management Spine 22:17S24S.
  • 37
    Apone S, Lee MY, Eyre DR 1997 Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone Bone 21:129136.
  • 38
    Colwell A, Eastell R 1996 The renal clearance of free and conjugated pyridinium cross-links of collagen J Bone Miner Res 11:19761980.
  • 39
    Beardsworth LJ, Eyre DR, Dickson IR 1990 Changes with age in the urinary excretion of lysyl- and hydroxylysyl-pyridinoline: Two new markers of bone collagen turnover J Bone Miner Res 5:671676.